Paul J. Clancy - 26 Oct 2021 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role: Director
Signature: /s/ Chris Frankenfield attorney-in-fact for Paul Clancy
Issuer symbol: XLO
Transactions as of: 26 Oct 2021
Net transactions value: $0
Form type: 4
Filing time: 26 Oct 2021, 17:01:05 UTC
Previous filing: 21 Oct 2021
Next filing: 04 Jan 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XLO	Stock Option (right to buy)	Award	$0	+44,033		$0.000000	44,033	26 Oct 2021	Common Stock	44,033	$5.51	Direct	F1
transaction	XLO	Stock Option (right to buy)	Award	$0	+65,528		$0.000000	65,528	26 Oct 2021	Common Stock	65,528	$5.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16, 2024.
F2	On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024.

Content

On July 23, 2020, the reporting person was granted an option to purchase 44,033 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's initial public offering ("IPO"). The Company's IPO closed as of October 26, 2021. On October 26, 2021, 13,760 shares underlying the award vested and the remainder will vest in equal monthly installments until July 16, 2024.

On March 11, 2021, the reporting person was granted an option to purchase 65,528 shares of common stock of the Company, the vesting of which was contingent upon the closing of the Company's IPO. The Company's IPO closed as of October 26, 2021. On October 26, 2021, 20,477 shares underlying the option vested and the remainder will vest in equal monthly installments until July 16, 2024.